Mist Therapy Optimizes Wound Bed

A new therapy called Mist is designed for wound cleaning and maintenance and has been recently been cleared by the U.S. Food and Drug Administration (FDA.)

Mist is indicated for debridement of wounds containing yellow slough, fibrin, tissue exudates, or bacteria, the removal of which are important for the healing process. The therapy can be used on a variety of wounds, including acute, traumatic, chronic, and dehisced wounds.

"The use of Mist therapy is an attractive technology for healthcare professionals since its use appears to enhance our ability to optimize the wound bed environment, thereby allowing these difficult-to-heal wounds to progress along the healing pathway,” said Dr. William Ennis, medical director of the wound treatment program at Advocate Christ Methodist Hospital in Chicago (IL, USA).

Mist was developed by Celleration, Inc. (Eden Prairie, MN, USA). The patented Mist technology utilizes low-intensity ultrasound waves to produce an energized mist of sterile saline in a noncontact fashion. "One half of all nontraumatic lower limb amputations result from wound complications,” explained Kevin Nickels, CEO and president of Celleration.




Related Links:
Celleration